Draegerwerk AG & Co. KGaA (DE:DRW3)
XETRA:DRW3
Want to see DE:DRW3 full AI Analyst Report?
Top Page
Draegerwerk AG & Co. KGaA
(XETRA:DRW3)
Select Model
Select Model
Rating:65Neutral
Price Target:
€97.00
▲(12.14% Upside)
Action:Downgraded
Date:05/02/26
The score is primarily supported by improving financial performance and a conservative balance sheet, but is held back by weaker cash-flow conversion/volatility, soft near-term technicals (below 20D/50D with subdued momentum), and a high P/E multiple despite a moderate dividend yield.
Positive Factors
Conservative balance sheet
Low leverage (debt-to-equity ~0.14) and meaningful equity provide durable financial flexibility. This reduces refinancing risk, supports investment or cyclical downturns, and enables the company to fund capex or service installed base without relying on high external debt.
Negative Factors
Weak cash-flow conversion
FCF covering only ~66% of net income and declining TTM implies earnings are not fully converting to cash. That constrains internal funding for capex, R&D, or working-capital swings and increases reliance on external financing if capex or inventories rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage (debt-to-equity ~0.14) and meaningful equity provide durable financial flexibility. This reduces refinancing risk, supports investment or cyclical downturns, and enables the company to fund capex or service installed base without relying on high external debt.
Read all positive factors
Draegerwerk AG & Co. KGaA (DRW3) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.44B
Dividend Yield2.95%
Average Volume (3M)7.90K
Price to Earnings (P/E)37.3
Beta (1Y)0.65
Revenue Growth4.23%
EPS Growth32.89%
CountryDE
Employees15,444
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)8.17
Shares Outstanding8,600,000
10 Day Avg. Volume7,731
30 Day Avg. Volume7,901
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.80
Price to Sales (P/S)0.37
P/FCF Ratio7.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€91.50Price Target Upside5.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)7.75
Revenue Forecast (FY)€3.62B
Draegerwerk AG & Co. KGaA Business Overview & Revenue Model
Company Description
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, inclu...
How the Company Makes Money
Dräger generates revenue primarily through the sale of products and associated services across two main segments: Medical and Safety. In the Medical segment, the company earns money from selling hospital and acute-care equipment (e.g., anesthesia ...
Draegerwerk AG & Co. KGaA Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
61
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.51B | 3.48B | 3.37B | 3.37B | 3.05B | 3.33B |
| Gross Profit | 1.59B | 1.52B | 1.51B | 1.46B | 1.24B | 1.54B |
| EBITDA | 385.77M | 384.83M | 351.68M | 318.33M | 62.63M | 374.43M |
| Net Income | 153.02M | 139.50M | 124.41M | 110.43M | -64.56M | 154.23M |
Balance Sheet | ||||||
| Total Assets | 3.17B | 3.28B | 3.09B | 3.09B | 3.11B | 3.18B |
| Cash, Cash Equivalents and Short-Term Investments | 269.09M | 284.06M | 248.18M | 279.36M | 319.50M | 577.38M |
| Total Debt | 225.68M | 405.11M | 395.58M | 471.38M | 361.95M | 348.01M |
| Total Liabilities | 1.51B | 1.65B | 1.56B | 1.69B | 1.79B | 1.92B |
| Stockholders Equity | 1.65B | 1.63B | 1.54B | 1.41B | 1.32B | 1.26B |
Cash Flow | ||||||
| Free Cash Flow | 160.29M | 166.50M | 103.52M | 121.47M | -231.09M | 274.54M |
| Operating Cash Flow | 244.41M | 238.33M | 167.31M | 189.68M | -144.23M | 384.89M |
| Investing Cash Flow | -92.15M | -98.15M | -43.39M | -67.34M | 36.83M | -109.92M |
| Financing Cash Flow | -130.85M | -83.99M | -161.38M | -154.56M | -29.38M | -334.64M |
Draegerwerk AG & Co. KGaA Technical Analysis
Positive
86.50
Price Trends
88.24
Negative
84.88
Positive
75.75
Positive
Market Momentum
-1.55
Positive
47.01
Neutral
18.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DRW3, the sentiment is Positive. The current price of 86.5 is below the 20-day moving average (MA) of 88.05, below the 50-day MA of 88.24, and above the 200-day MA of 75.75, indicating a neutral trend. The MACD of -1.55 indicates Positive momentum. The RSI at 47.01 is Neutral, neither overbought nor oversold. The STOCH value of 18.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:DRW3.
Draegerwerk AG & Co. KGaA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | €909.83M | 22.05 | 20.26% | 1.11% | 6.84% | 43.33% | |
66 Neutral | €2.26B | 36.10 | 6.77% | 1.50% | -0.06% | -38.81% | |
65 Neutral | €1.44B | 37.27 | 9.79% | 2.95% | 4.23% | 32.89% | |
61 Neutral | €37.56B | 20.17 | 11.59% | 2.13% | -0.33% | 0.15% | |
60 Neutral | €1.43B | 49.73 | 4.19% | 0.20% | 1.16% | -43.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €206.65M | -30.34 | -0.10% | 2.71% | ― | ― |
* Healthcare Sector Average
DE:DRW3
Draegerwerk AG & Co. KGaA
87.60
24.44
38.69%
DE:AFX
Carl Zeiss Meditec
25.24
-34.96
-58.07%
DE:COP
CompuGroup Medical
27.15
5.54
25.66%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
14.79
-6.46
-30.41%
DE:SBS
STRATEC Biomedical
16.88
-9.56
-36.17%
DE:SHL
Siemens Healthineers AG
33.86
-14.06
-29.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.